14 completed, 10 terminated, 8 recruiting, 5 not yet recruiting. 25 Phase 2, 12 Phase 3, 10 Phase 1, 2 Not applicable, 1 Phase 4.
Follow taxane: new trials by email Literature Review of taxane trials Research Report on taxane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 43 | 2026-11-01 | 2026-10-22 |
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | 28 | 2026-10-01 | 2026-10-13 |
| Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 240 | 2026-10-01 | 2026-07-21 |
| Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer THP Regimen (Taxane + Trastuzumab + Pertuzumab), Trastuzumab Rezetecan (SHR-A1811) - HER2-positive Breast Cancer | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 124 | 2026-03-24 | 2026-06-15 |
| ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors ABL103, KEYTRUDA® (pembrolizumab), Taxane - Solid Tumors | Phase 1 / Phase 2 | Recruiting | ABL Bio, Inc. | 65 | 2025-08-06 | 2025-09-08 |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer Organoid-guided treatment, Taxane, Capecitabine - HER2-negative Breast Cancer, Advanced Breast Cancer | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 252 | 2024-10-01 | 2024-11-25 |
| Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum - Triple-negative Breast Cancer | Phase 2 | Unknown | Fudan University | 10 | 2024-05-20 | 2024-07-08 |
| Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer Inosine, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum - Triple-negative Breast Cancer | Phase 2 | Completed | Fudan University | 10 | 2024-05-11 | 2025-07-18 |
| Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer Taxane and Carboplatin, Short-term Sintilimab, Surgery - Triple-negative Breast Cancer | Phase 4 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 48 | 2023-07-01 | 2023-06-06 |
| Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI - Breast Cancer, ER-positive Breast Cancer | Phase 2 | Active not recruiting | University of Miami | 24 | 2023-06-12 | 2026-01-13 |
| Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study Cisplatin, Computed Tomography, Gastrectomy - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 40 | 2023-04-20 | 2026-04-08 |
| Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform Whole Genome Sequencing, RNA-Sequencing, Microbiome analysis - Triple Negative Breast Cancer | Recruiting | Vall d'Hebron Institute of Oncology | 100 | 2023-01-13 | 2023-06-23 | |
| Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL) Pulsed electromagnetic fields (PEMFs), Device: Pulsed electromagnetic fields (PEMFs); Drug: Anthracycline OR Taxane - Breast Cancer | Phase 1 | Completed | National University Hospital, Singapore | 14 | 2022-12-30 | 2026-03-13 |
| A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer BMS-986442, Nivolumab, Docetaxel - Advanced Solid Tumors, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 36 | 2022-10-04 | 2025-03-18 |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin - Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer | Phase 3 | Recruiting | Genelux Corporation | 186 | 2022-08-31 | 2026-08-26 |
| Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer Taxane plus Intermittent Capecitabine, Utidelone plus Intermittent Capecitabine, Taxane plus Metronomic Capecitabine - Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 512 | 2022-03-01 | 2021-12-29 |
| Real-world Data (RWD) of Ramucirumab Plus Paclitaxel Ramucirumab and paclitaxel, Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Unknown | Hallym University Medical Center | 222 | 2021-06-01 | 2021-06-07 | |
| Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) Trastuzumab deruxtecan, Placebo, Taxane - Breast Cancer; HER2-positive; Metastatic | Phase 3 | Active not recruiting | AstraZeneca | 1157 | 2021-04-26 | 2026-10-22 |
| Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients Taxane - HER2-positive Gastric Cancer, Metastatic Cancer | Completed | Centre Hospitalier Universitaire de Besancon | 65 | 2021-04-01 | 2021-06-10 |
Showing 20 of 49. Sign in to see all of them.
Breast Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (7) · Triple Negative Breast Neoplasms (7) · Ovarian Neoplasms (6) · Fallopian Tube Neoplasms (4) · Neoplasm Metastasis (3) · Stomach Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Lung Neoplasms (2) · Neoplasms (2) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Breast Diseases (1) · Carcinoma, Small Cell (1) · Colonic Neoplasms (1)
Bristol-Myers Squibb (5) · Fudan University (3) · Hoffmann-La Roche (2) · Peregrine Pharmaceuticals (2) · Shanghai Gynecologic Oncology Group (2) · Sun Yat-sen University (2) · ABL Bio, Inc. (1) · AstraZeneca (1) · Bayer (1) · Biogen (1) · Calithera Biosciences, Inc (1) · Centre Hospitalier Universitaire de Besancon (1) · Eli Lilly and Company (1) · EpicentRx, Inc. (1) · GBG Forschungs GmbH (1)
United States (28) · China (11) · Spain (8) · Canada (7) · Italy (7) · France (6) · Germany (6) · South Korea (6) · Belgium (5) · United Kingdom (5) · Australia (4) · Brazil (4) · Hungary (4) · Mexico (4) · Netherlands (4)
Bryan Oronsky, MD, PhD (1) · Charles J Nock, MD (1) · Dae Young Zang (1) · David Page, MD (1) · Frances Valdes-Albini, MD (1) · Ian Rabinowitz, MD (1) · Jenny C Chang, MD (1) · Jihong Liu, PhD (1) · Kathy Miller, MD (1)
PMID 24051172, PMID 28343975, PMID 30706247, PMID 31231122, PMID 31383985, PMID 32183229, PMID 32319233, PMID 33569311, PMID 34439284, PMID 34686353, PMID 35340264, PMID 37166557, PMID 37227734, PMID 37666539, PMID 37883329, PMID 41160818
2008 (2), 2015 (1), 2019 (1), 2023 (1), P30CA014520 (1), R01CA234904 (1), U10CA180888 (1)